Moving to slide nine, At CIT, fourth quarter revenue grew over 19% year over year, evidence of continued progress in both its commercial aerospace and medical technology platforms. Encouragingly, in commercial aerospace, backlog is now at levels not seen since March of 2020. We are encouraged by the growing demand related to narrow-body production driven by steady rebound in global domestic air travel. Longer term, as demand for wide-body production returns with the resumption of international travel, CIT will be well positioned to capture and leverage that growth. Over the past several quarters, CIT has taken significant restructuring actions to drive improved profitability. The impact of these actions has shown over the past several quarters driving CIT's profitability on an adjusted EBITDA basis to swing to positive year-over-year growth in the second half of 2021 as the resumption of revenue growth drives greater leverage. On the medical side, the team delivered record fourth quarter revenue as hospital capital spending resumes. Longer term, as our medical business gains momentum and adds to its current record backlog, we believe the platform is well positioned to drive and leverage mid to high single-digit annual growth going forward.

Feb 10, 2022 / CEO / receipt, needs a key / Chris Koch, CEO | earnings call 2022-02-10 | transcript 0c97fd35-3d51-4fc9-bb37-f8e8baee505f | chars 16701-17960 | segment 17

We are following best practices and guidance from recognized authorities on employee health and safety measures, including safe hygiene and social distancing, enhanced facility cleaning and disinfecting, travel and facility access restrictions, and telecommuting where practical.

Apr 21, 2020 / CEO / receipt, needs a key / Chris Koch, CEO | earnings call 2020-04-21 | transcript 63946d7e-fc26-4cda-ab05-af95342a6746 | chars 3609-3888 | segment 3